Supplemental material
Human Vaccines & Immunotherapeutics
Volume 16, 2020 - Issue 4
Research Paper
Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines
, , , , 
, , & show all
Tomáš Marčekd MCM Vaccine B. V., Leiden, The Netherlandshttps://orcid.org/0000-0003-0920-4192View further author information
https://orcid.org/0000-0003-0920-4192View further author information, , Camilo J. Acostab Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0002-2313-3493View further author information
https://orcid.org/0000-0002-2313-3493View further author information & show allRelated Research Data
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
Source:
Elsevier BV
Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination
Source:
Elsevier BV
Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
Source:
Ovid Technologies (Wolters Kluwer Health)
Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy.
Source:
Elsevier BV
Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Source:
Elsevier BV
The value of childhood combination vaccines: From beliefs to evidence
Source:
Informa UK Limited
Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up
Source:
Springer Science and Business Media LLC
Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report.
Source:
Elsevier BV
Bordetella pertussis fimbriae (Fim): relevance for vaccines.
Source:
Informa UK Limited
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
Source:
Ovid Technologies (Wolters Kluwer Health)
Nationwide vaccination: A success story in Taiwan
Source:
Elsevier BV
Long-term Protection After Hepatitis B Vaccine
Source:
Oxford University Press (OUP)
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
Source:
Ovid Technologies (Wolters Kluwer Health)
Correlates of Protection Induced by Vaccination
Source:
American Society for Microbiology
A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
Source:
Elsevier BV
Protection against hepatitis B after 20 years
Source:
Wiley
Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan.
Source:
Elsevier BV
Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response.
Source:
Elsevier BV
A 15-Year Follow-Up Study
Source:
Ovid Technologies (Wolters Kluwer Health)
Linking provided by
